Directorate Change

Graft Polymer (UK) Plc (LON: GPL), an innovative biopolymer drug delivery systems development company, announces the resignation, with immediate effect, of Mr. Victor Bolduev from its board of directors and from his role as the Company's Chief Technology Officer. Mr Bolduev's resignation follows :

• the Company's divestiture of its industrial plastics business unit, Graft Polymer D.O.O., in early May 2024; and
• the Company's prioritisation of opportunities in the healthcare industry, including the recently announced collaboration agreement with Awakn Life Sciences Corp (CSE:AWKN OTCQB:AWKNF) and the appointment, on 30 July 2024, of Professor David Nutt as the Company's Senior Scientific Adviser.

Graft Polymer plc ("Graft Polymer") (LON: GPL) is an innovative biopolymer drug delivery systems development company dedicated to enabling biopharmaceutical companies to enhance the effectiveness of their therapeutics. Our proprietary platform, a bioabsorbable self-nanoemulsifying drug delivery system (SNEDDS), represents a cutting-edge solution in drug delivery technology. By integrating active pharmaceutical ingredients (APIs) into our novel, patented delivery systems, we enable clients to improve the pharmacokinetics, bioavailability, and stability of their therapeutics..

For more information, please visit www.graftpolymer.co.uk.